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Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology, and life expectancy of
3-5 years after diagnosis. The incidence rate in the United States is estimated as high as 15
per 100,000 persons per year. The disease is characterized by repeated injury to the alveolar epithelium, resulting in inflammation and deregulated repair, leading to scarring of the
lung tissue, resulting in progressive dyspnea and hypoxemia. The disease has no cure,
although new drugs are in clinical trials and two agents have been approved for use by the
FDA. In the present paper we develop a mathematical model based on the interactions
among cells and proteins that are involved in the progression of the disease. The model
simulations are shown to be in agreement with available lung tissue data of human patients.
The model can be used to explore the efficacy of potential drugs.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a disease in which scar tissue in the lung is deposited;
the deposition of the scar tissue is called fibrosis. As the disease progresses, alveolar-capillary
units are impacted, oxygen and carbon dioxide exchange is impaired, ultimately leading to
respiratory failure. IPF usually affects older people [1], but its etiology is unknown. IPF has no
cure yet, and life expectancy is 3-5 years after diagnosis [2]. IPF is characterized by repeated
injury to alveolar epithelium. The injury results in loss of alveolar epithelial cells (AECs) due to
increased apoptosis, epithelial to mesenchymal transition (EMT), and abnormal tissue repair
[3]. Oxidative stress is associated with the disregulation of the AECs [4, 5], and inflammation is
initiated by damaged AECs [6]. Fibrocytes, bone marrow mesenchymal progenitor cells circulating in the blood, play a role in wound repair and are increased in lungs of patients with IPF.
However, fibrocyte numbers do not correlate with disease severity [7, 8].
Inflammation and injury activate AECs [9, 10, 11], and activated AECs secrete a number of
pro-inflammatory mediators including tumor necrotic factor alpha (TNF-α) [12, 13] and chemoattractant monocyte chemotactic protein-1 (MCP-1) [7, 14, 15]. MCP-1 recruits circulating
monocytes from the blood into damaged lung tissue, where they differentiate into classically
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activated macrophages M1.In normal lung tissue (homeostasis), macrophages from blood
monocytes develop into alveolar macrophages (AM) [12, 16]. Alveolar macrophages are often
referred to as alternatively activated macrophages, or M2 macrophages. However M2 macrophages are heterogeneous, and in IPF there appears to be a shift from monocyte-derived M1
macrophages to pro-fibrotic M2 macrophages [17, 18]. These M2 macrophages are responsible
for the progression from inflammation to interstitial fibrosis [2, 18] by secreting plateletderived growth factor (PDGF) [19, 17], transforming growth factor-beta (TGF-β) [17], matrix
metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) [17], all of which
are involved in the regulation of tissue fibrosis. TGF-β is produced also by fibroblasts activated
by AEC [12, 20]. Both TGF-β and reactive oxygen species increase AEC apoptosis [20].
TNF-α is produced by the proinflammatory macrophages as well as by activated AEC, and
it induces polarization of M2 into M1 [21] which helps to resolve the fibrosis. This polarization
by TNF-α is resisted by IL-13 [22, 23, 24] which is produced by M2 macrophages and TH2
lymphocytes [25]. On the other hand, MMP28 [26] and other extracellular matrix (ECM) molecules (e.g. monomeric collagen type 1 interacting with CD204 on M1 [17]) activate polarization of M1 into M2 macrophages. TGF-β, along with AEC-derived basic fibroblast growth
factor (bFGF) increase the proliferation of interstitial fibroblasts [6, 20]. PDGF and TGF-β
transform fibroblasts into myofibroblasts [27, 28, 29, 30], which together with fibroblasts produce ECM. Imbalance between MMP and its inhibitor TIMP facilitates the accumulation of
ECM and the formation of fibrosis [31].
Fibrosis is a disease in which scar tissue develops in an organ resulting in loss of functionality of the organ. Although this process evolves in nearly identical way in all organs, there may
be some aspects which are organ specific. Recently Hao et. al. [32] developed a mathematical
model of renal interstitial fibrosis and demonstrated that the model can be used to monitor the
effect of treatment by anti-fibrotic drugs that are currently being used, or undergoing clinical
trials, in non-renal fibrosis. The present paper is based on the model developed in [32] but in
addition in includes two features that are unique to pulmonary fibrosis. The first one is the fact
that in lung fibrosis we need to deal with two phenotypes of macrophages: monocyte-derived
inflammatory macrophages (M1) and anti-inflammatory alveolar macrophages (M2). The network shown in Fig 1 is similar to the network in Fig 1 of [32], but in the present figure the macrophages are divided into M1 and M2 phenotypes, and they play different roles in the fibrotic
process.
The second unique feature in lung fibrosis is the geometry of the lung which includes a very
large number of alveoli. This complex geometry is represented, in a simplified form, in Fig 2.
Our mathematical model of IPF is based on Fig 1 combined with ‘homogenization’ method
associated with Fig 2.
The present paper develops for the first time a mathematical model of IPF. The model is
based on the experimental and clinical information referenced above, schematically summarized in the network shown in Fig 1. The model is represented by a system of partial differential
equations. The model is validated by comparing the simulation results with patients data and
may be used to test the efficacy of potential drugs in stopping the patient’s growth of fibrosis.

Materials and Methods
Mathematical model
Table 1 lists all the variables of the model in units of g/cm3. For the purpose of mathematical
modeling we use a simple representation of the lung geometry, whose 2-dimensional projection
is shown in Fig 2. The tissue under consideration is a cube R with edge-size 1 cm. The cube is
partitioned by periodically arranged small cubes Tε with edge-size ε, and in each ε-cube there
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Fig 1. Schematic network of cells and proteins in IPF.
doi:10.1371/journal.pone.0135097.g001

is a concentric cube Aε of edge-size (1 − θ)ε; the Aε represent the alveoli air space, and the
domains Tε/Aε represent the alveolar tissue. An alveolar diameter is approximately 140 μm
[33] and the thickness of the arterial wall which contains the capillaries, epithelial cells and
fibroblasts is 10 μm. We correspondingly take 1y
¼ 6, i.e., θ = 1/7. The dimensions of a lung
y
are 12 × 31 × 41 cm3, and there are approximately 350 million alveoli in a lung. Hence ε is
extremely small.
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Fig 2. Lung geometry consists of a periodically arranged cubes with smaller cubes representing the air space of alveoli.
doi:10.1371/journal.pone.0135097.g002

We first write down all the differential equation in Tε/Aε, and then take ε ! 0 to obtain the
homogenized system in the cube R. The variables that will be used in the model are given in
Table 1.
Equation for macrophage density. The equation for macrophage density in Tε/Aε (coming from the blood) is given by
@M1
 DM r2 M1
@t

Ta
¼ r  ðM1 wP rPÞ dM1 M1 þ lMT
M lM1 M1 :
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} |ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
KTa þ Ta 2 |ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} M1 !M2
chemotaxis
apoptosis
M2 !M1
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Table 1. The variables of the model in units of g/cm3.
M1:

density of M1 macrophages

E0:

density of AEC

M2:

density of M2 macrophages
density of activated AEC

E

f:

density of ﬁbroblast

m:

density of myoﬁbroblast

ρ:

density of ECM

P:

concentration of MCP-1

G:

concentration of PDGF

Tβ:

concentration of activated TGF-β

Q:

concentration of MMPs

Qr:

concentration of TIMP

Tα

concentration of TNF-α

I13

concentration of IL-13

S

scar density

doi:10.1371/journal.pone.0135097.t001

Macrophages are terminally differentiated cells; they do not proliferate. They differentiate from
monocytes that are circulating in the blood and are attracted by MCP-1 into the lung tissue.
Hence they satisfy the boundary condition
DM

@M1 ~
þ bðPÞðM0  M1 Þ ¼ 0 on @Tε :
@n

~
where bðPÞ
depends on MCP-1 concentration, P. Here M0 denotes the density of monoctyes in
the blood, i.e., the source of M1 macrophages from the vascular system. We note that the above
Robin boundary condition arises from boundary homogenization of the vascular system, as
a
M2 accounts for transformation from M2 to M1
done, for example, in [34]. The term lMT KT TþT
a
a

induced by TNF-α [21]. The term −r(M1χPrP) is the chemotactic effect of MCP-1 on M1
macrophages; χP is the chemotactic coefﬁcient. As noted in the Introduction, macrophages
from blood monocytes evolve into AM [12, 16] and, in IPF, there is a shift from AM to proﬁbrotic M2 macrophages. There is also a polarization from M1 to M2 induced by MMP28
[26], and by collagen type I via CD204 receptor on M1 [17]. The term λM1M1 represents polarization from M1 to M2 by the above processes and possibly other processes (e.g. [35]).
We want replace the boundary condition of M1, by a spatial distribution f. If DMr2u = f in
R
R
¼ 0 on @Aε, DM @u
¼ g on @Tε, then, by integration Tε/Aε fdV = @Tε gdS. Hence
Tε/Aε, @u
@n
@n
f  volume of T =A ¼ g  area of @T ;
ε
ε
ε
where f and g are the mean values of f and g. Since
volume of Tε =Aε ¼ ε3 ½1  ð1  yÞ  ¼ gε2 ;
3

area of @Tε ¼ 6ε2 ;

where γ = 127/343, and ε is small so that f  f and g  g, we can replace the boundary con~
dition of M1 by the spatial distribution 6εbðPÞ=g
¼ bðPÞ. Hence, the equation for M1 density
in Tε/Aε is given by
@M1
 D M r2 M 1
@t

¼ bðPÞðM0  M1 Þ  r  ðM1 wP rPÞ  dM1 M1
þ lMT

Ta
M  lM1 M1 ;
KTa þ T a 2

ð1Þ

with zero boundary ﬂux. We take bðPÞ ¼ b KPPþP, where β is a constant

PLOS ONE | DOI:10.1371/journal.pone.0135097 September 8, 2015

5 / 19

Mathematical Model of IPF

The M2 macrophage density satisfies the equation
@M2
 D M r2 M 2
@t

Ta
¼ lM1 M1 dM2 M2 lMT
M;
|ﬄﬄ{zﬄﬄ} |ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
KTa þ T a 2
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
M1 !M2
apoptosis

ð2Þ

M2 !M1

where the first and last terms on the right-hand side are complimentary to the corresponding terms in Eq (1).
Equation for AEC density (E0 and E). The equation of the inactivated AEC density is
given by
0
1
!
B
Tb
dE0
l1 E0 ID C
B
C
¼ AE0 B1 þ
lE0 E0 ID :
C dE0 E0 1 þ d þ dE0 T
ð3Þ
@
dt
KD þ E0 ID A
KTb þ Tb
|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
|ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ} |ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ
ﬄ}
E0 !E
repair

apoptosis

In normal healthy, the production of E0 is represented by the term AE0 and the death rate is represented by dE0E0.
The equation for the activated AEC is
dE
dt

¼

lE0 E0 ID lEM EID dE E :
|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ} |ﬄﬄ{zﬄﬄ}
|ﬄﬄﬄ{zﬄﬄﬄ}
EMT

activation

ð4Þ

apoptosis

In homeostasis, ID = ;, δ = 0 and activated TGF-β concentration is very small. The injury to the
epithelium is expressed in two ways: (i) by activation of AEC, which is represented by term
λE0E0ID, where D is the damaged region and ID = 1 on D and ID = 0 elsewhere, and (ii) by
increased apoptosis caused by oxidative stress [4, 5] (the term δ) and by TGF-β [20, 3]. In IPF,
the damaged epithelium is partially repaired by ﬁbrocytes, and this is expressed by the term
l1 E0 ID
[7]. The second term of the right-hand side in Eq (4) accounts for EMT due to injury [3].
KD þE0 ID
Equations for fibroblast density (f) and myofibroblast density (m). The fibroblasts and
myofibroblasts equations are given by:
!
Tb
@f
I13
E
2
f df f
 Df r f ¼ lEf E0 þ lfE
þ
KTb þ Tb KI13 þ I13 KE þ E |ﬄ{zﬄ}
@t
|ﬄ{zﬄ}
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} apoptosis
source
production

!
Tb
G
f ;
 lmfT
þ lmfG
KTb þ T b
KG þ G
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}

ð5Þ

f !m

@m
 Dm r 2 m
@t

!
Tb
G
f dm m :
¼
lmfT
þ lmfG
|ﬄﬄ{zﬄﬄ}
KTb þ Tb
KG þ G
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} apoptosis

ð6Þ

f !m

The ﬁrst term on the right-hand side of Eq (5) is a source from E0-derived bFGF, which for
simplicity we take to be in the form λEfE0. As in [32], TGF-β and PDGF transform ﬁbroblasts
into myoﬁbroblasts [27, 28, 29, 30]. Furthermore, TGF-β and IL-13 [22, 23, 24], along with Ederived bFGF, increase proliferation of ﬁbroblasts [6, 32, 27]. For simplicity, we do not include
bFGF speciﬁcally in the model, but instead represent it by E. The production of ﬁbroblasts in
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healthy normal tissue depends on the density of AECs in homeostasis, and is represented by
the term λEfE0 [6, 20].
Equation for ECM density (ρ) and scar (S). The ECM, produced by fibroblasts and myofibroblasts [27, 28, 29, 30], is degraded by MMP [36], and TGF-β enhances the production of
ECM by myofibroblasts [27, 28, 29, 30]. The equation for the density of ECM is then given (as
in [32]) by:
!

þ
Tb
@r
r
¼ lrf f 1 
m
þ lrm 1 þ lrTb
KTb þ T b
@t
r0
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
ð7Þ
production
dr r  drQ Qr ;
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
degradation


þ

þ
where 1  rr0 ¼ 1  rr0 if ρ < ρ0, 1  rr0 ¼ 0 if ρ  ρ0.
Excessive accumulation of ECM components (particularly collagen) associated with tissue
injury and inflammation, results in permanent scar formation [37]. Within each type of scar,
there is considerable heterogeneity: an imbalance between MMP and TIMP activity has been
implicated in the development of scar [31]. Thus a scar depends on production and deposition
of ECM and disruption of normal, healthy protein cross-linking. We define the scar simply by
the equation
S ¼

þ

ð8Þ

lS ðr  r Þ ;

where ρ is the ECM density in homeostasis and λS is a constant, but this deﬁnition is a simpliﬁed characterization of a scar since it does not account for disruption in protein cross-linking.
Equation for MCP-1 (P). The MCP-1 equation is given by
@P
 DP r 2 P
@t

¼

P
M ;
lPE E dP P  dPM
|ﬄ{zﬄ}
KP þ P 1
production |ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}

ð9Þ

degradation

where λPE represents the growth rate by activated AEC following damage to the endothelium
[32, 7, 14, 15, 1]. The last term accounts for the internalization of MCP-1 by macrophage,
which may be limited due to the limited rate of receptor recycling.
Equations for concentrations of PDGF (G), MMP (Q), TIMP (Qr), TGF-β (Tβ), TNF-α
(Tα) and IL-13 (I13). As in [32], the following sets of diffusion equations hold for G, Q and Qr:
@G
 D G r2 G
@t

¼ lGM M2
|ﬄﬄﬄ{zﬄﬄﬄ}
production

@Q
 D Q r2 Q
@t

depletion

depletion

ð11Þ

degradation

¼ lQr M M2 dQr Q QQr dQr Qr :
|ﬄﬄﬄ{zﬄﬄﬄ} |ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ} |ﬄﬄﬄ{zﬄﬄﬄ}
production

ð10Þ

degradation

¼ lQM M2 dQQr Qr Q dQ Q ;
|ﬄﬄﬄ{zﬄﬄﬄ} |ﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄ} |ﬄﬄ{zﬄﬄ}
production

@Qr
 D Q r r2 Q r
@t

dG G ;
|ﬄﬄ{zﬄ
ﬄ}

ð12Þ

degradation

Note that in Eq (11), MMP is lost by binding with TIMP (second term).
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As in [32], TGF-β is produced and activated by M2 macrophages while enhanced by IL-13
[22, 23, 24]; in addition, TGF-β is produced and activated by fibroblasts and AEC [12, 20]:
!
@Tb
I
E
13
 DTb r2 Tb ¼ lTb M M2 1 þ lTb I13
þ lTb f f
dTb Tb :
@t
I13 þ KI13
E þ KE |ﬄﬄﬄ{zﬄﬄﬄ}
ð13Þ
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} degradation
production

TNF-α is produced by M1 macrophages [21], and is also produced by AEC [12, 13]:
@Ta
 D Ta r 2 T a
@t

¼

Ta
lTa M M1 þ lTa E E dTa Ta lMTa
M :
KTa þ T a 2
|ﬄﬄﬄ{zﬄﬄﬄ}
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
production
degradation |ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}

ð14Þ

M2 !M1

IL-13 is produced by M2 macrophages [22, 23], and follows the equation
@I13
 DI13 r2 I13
@t

¼ lI13 þ lI13 M M2 dI13 I13 :
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} |ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
production

ð15Þ

degradation

Actually, IL-13 is also produced by TH2 cells [25]; for simplicity we do not include TH2 cells
in our model but accounts for their production of IL-13 by the term λI13.
The homogenized equations. On the boundary of Tε/Aε all the variables are assumed to
have zero flux. Hence, each of the Eqs (1)–(14), if written in the form
@X
 DX r2 X ¼ FX ðXÞ in Tε =Aε ;
@t

ð16Þ

takes, after homogenization [38] (Sec. 3.1 and p.31), the following form:
g

@X
 DX r~2 X ¼ gFX ðXÞ in the cube R;
@t

ð17Þ

P
2
. Here r~2 ¼ aij @x@i @xj ,
where γ is the volume fraction of the tissue in each ε-cube, g ¼ 127
343
where the coefﬁcient aij are computed by
Z
aij ¼


dij þ
y2T=A


@wj
dy:
@xi

where χi satisﬁes the equation
r2 wi ¼ 0 in T n A; with

@wi
þ ni ¼ 0 on the boundary of A;
@n

here T ¼ Tεε , A ¼ Aεε , ni is the i-th component of the outward normal n, and χi is periodic in the
directions of the three axes xj (j = 1,2,3). Computing aij by ﬁnite element discretization, we ﬁnd
(similarly to [32]) that aii = 0.11 (i = 1,2,3) and aij = 0 if i 6¼ j.

Boundary conditions
All variables are assumed to satisfy the zero flux boundary condition on @R, the boundary of
the cube R.
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Initial conditions
We assume initial homeostasis, that is, λE0E0ID = 0, but with a small amount of inflammation,
represented by the term λPEE in Eq (9). We take this term to be 10−10 and compute the initial
values by solving the steady state equations.
In particular we find the initial values of Tα = 2.5 × 10−8, Tβ = 2.51 × 10−12 and I13 = 3.2 × 10−8
in units of gm/ml. Taking into account that only γ-fraction of the space is occupied by tissue, the
values 1g Ta , 1g I13 coincide with the concentration of Tα and I13 measured in the bronchial tubes of
healthy lung in [39], and 1g Tb coincides with value of TGF-β as computed in [40].

We also compute that E0 = E = 0.79 g/cm3, f = f = 4.75 × 10−3 g/cm3, ρ = ρ = 3.26 × 10−3
g/cm3 and I13 = 1.76 × 10−8 g/cm3 at t = 0.

Results
Numerical scheme
We briefly describe the technique used in the simulations, and for simplicity take R to be the
unit cube, i.e., R = [0, 1] × [0, 1] × [0, 1]. Consider the following general diffusion equation
@C
 DC r2 C ¼ FC ðCÞ;
@t
in R with zero ﬂux on @R. Given three positive integers K1, K2, K3, let
xi ¼ i=K1 ; yj ¼ j=K2 ; zk ¼ k=K3 ; 0

i

K1 ; 0

j

K2 ; 0

k

K3 :

Then we denote ci, j, k(t) the numerical approximation of C(xi, yj, zk, t), and get the following
ODE system by semi-discretization:
dci;j;k ðtÞ
@t

¼ DC ðK12 ½ciþ1;j;k ðtÞ þ ci1;j;k ðtÞ  2ci;j;k ðtÞ þ K22 ½ci;jþ1;k ðtÞ þ ci;j1;k ðtÞ  2ci;j;k ðtÞ

ð18Þ

þ K ½ci;j;k1 ðtÞ þ ci;j;kþ1 ðtÞ  2ci;j;k ðtÞÞ þ FC ðci;j;k ðtÞÞ:
2
3

The Runge-kutta method is employed to solve this ODE system. The above method is used to
solve the coupled system of equations of the complete model.

Model simulation and validation
In this section, we simulate the model (1)-(17). The parameter values are listed in Tables 2 and
3 and the initial values are taken as explained above. The numerical simulation were carried
out by finite difference scheme in spatial direction and Runge-Kutta method in time direction.
Fig 3 shows the dynamics of the average densities of cells and concentrations of cytokines
for 30 days.
Fig 4 shows histogram of cells and cytokines in disease vs. homeostasis. The simulation
results for MMP and TIMP shown in Fig 4 are in agreement with the experimental results,
reported in [41] for protein concentration human lung tissue with IPF (n = 16 human subjects)
and control (n = 6 human subjects). Indeed, although (in [41]) MMP 7 (for IPF) is nearly 4
times the level of MMP7 for control, all other MMPs (1,2,9,13) increased approximately twice
or just a little more than twice, while the relatively small concentration of MMP8 decreased to
25% of the control level. The simulation results for TIMP shows an increase of 20% in the protein concentration for IPF vs. control, which is the same as in human lung tissues reported in
[41] for TIMP-1,2,3. Levels of mRNA expression relate to levels of the translated proteins. The
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Table 2. Parameters’ description and value.
Parameter

Description

Value
−7

8.64 × 10

cm2 day−1 [32]

DM

dispersion coefﬁcient of macrophages

DP

diffusion coefﬁcient of MCP-1

1.728 × 10−1 cm2 day−1 [32]

DG

diffusion coefﬁcient of PDGF

8.64 × 10−2 cm2 day−1 [32]

DQ

diffusion coefﬁcient of MMP

4.32 × 10−2 cm2 day−1 [32]

DQ r

diffusion coefﬁcient for TIMP

4.32 × 10−2 cm2 day−1 [32]

DTβ

diffusion coefﬁcient forTGF-β

4.32 × 10−2 cm2 day−1 [32]

DTα

diffusion coefﬁcient for TNF-α

1.29 × 10−2 cm2 day−1 [55]

Df

dispersion coefﬁcient ofﬁbroblasts

1.47 × 10−6 cm2 day−1 [32]
1.47 × 10−5 cm2 day−1 [32]

Dm

dispersion coefﬁcient of myoﬁbroblasts

DI13

diffusion coefﬁcient of IL-13

1.08 × 10−2 cm2 day−1 [40]

DTα

diffusion coefﬁcient forTNF-α

1.29 × 10−2 cm2 day−1 [40]

λMT

transition rate of M2 to M1 macrophages by TNF-α

5 × 10−3 day−1 [56]

λM1

polarization rate of M1 to M2 macrophages

9.02 × 10−6 day−1, estimated

λE0

AEC

λ1

0.25 day−1 estimated
−3

g/cm3 day−1 estimated

repair rate of AEC

10

1.65 × 10−3 day−1 estimated

λEM

EMT rate of AEC

λTβM

production rate of TGF-β by macrophages

1.5 × 10−2 day−1 [32]

λTβf

production rate of TGF-β by ﬁbroblast

7.5 × 10−3 day−1 [32] & estimated

λGM

production rate of PDGF by macrophages

2.4 × 10−5 day−1 [32]

λQM

production rate of MMP by macrophages

3 × 10−4 day−1 [32]

λQrM

production rate of TIMP by macrophages

6 × 10−5 day−1 [32]

λPE

activation rate of MCP-1 due to AECs

1 × 10−8 day−1 [32]

λρf

activation rate of ECM due to ﬁbroblasts

3 × 10−3 day−1 [32]

λρm

activation rate of ECM due to myoﬁbroblasts

6 × 10−3 day−1 [32]

λρTβ

activation rate of ECM due to TGF-β

2 [32]

λEf

activation rate of ﬁbroblasts due to bFGF and TGF-β

2.5 × 10−1 day−1 [32] & estimated

λfE

production rate of ﬁbroblasts

5 × 10−4 day−1 [32] & estimated

λmfT

activation rate of myoﬁbroblasts due to TGF-β

0.12 day−1 [32]

λmfG

activation rate of myoﬁbroblasts due to PDGF

0.12 day−1 [32]

λTαM

activation rate of TNF-α due tomacrophage

1.39 × 10−5 day−1 [57]

λTαE

activation rate of TNF-α due tomacrophage

6.9 × 10−6 day−1 [57] & estimated

λI13

production rate of IL-13 by Th2 cells

2.12 × 10−7 g/ml day−1 [40]

λI13M

production rate of IL-13 by macrophages

3.98 × 10−4 day−1 [40]

dM 2

death rate of macrophages

0.015 day−1 [32]

dM 1

death rate of macrophages

0.02 day−1 [56, 58]

dE

death rate of AECs

1.65 × 10−2 day−1 [32]

dE0

death rate of AECs

1.65 × 10−2 day−1 [32]

dE0T

death rate of AECs

1.65 × 10−3 day−1 [32]

δ

increased death rate of AECs by injury

1 × 10−3 day−1, estimated

dρ

degradation rate of ECM

0.37 day−1 [32]

dP

degradation rate of MCP-1

1.73 day−1 [32]

dPM

internalization rate of MCP-1 by M1 macrophages

2.08 × 10−4 day−1 [32]

dG

degradation rate of PDGF

3.84 day−1 [32]

dQQr

binding rate of MMP to TIMP

4.98 × 108 cm3 g−1 day−1 [32]

dQrQ

binding rate of TIMP to MMP

1.04 × 109 cm3 g−1 day−1 [32]

dQ

degradation rate of MMP

4.32 day−1 [32]

dQ r

degradation rate of TIMP

21.6 day−1 [32]

dρQ

degradation rate of ECM due to MMP

2.59 × 107 cm3 g−1 day−1 [32]

dT β

degradation rate of TGF-β

3.33 × 102 day−1 [32]

df

death rate of ﬁbroblasts

1.66 × 10−2 day−1 [32]

dm

death rate of myoﬁbroblasts

1.66 × 10−2 day−1 [32]

dT α

degradation rate of TNF-α

55.45 day−1 [59]

dI13

degradation rate of IL-13

12.47 day−1 [40]

doi:10.1371/journal.pone.0135097.t002
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Table 3. Parameters’ description and value.
Parameter

Description

Value

χP

chemotacticsensitivity parameter by MCP-1

10 cm g−1 day−1 [32]

AE0

intrinsic AEC proliferation

8.27 × 10−3 g/cm3 day−1 [32]

KG

PDGF saturation for activation of myoﬁbroblasts

1.5 × 10−8 gcm−3 [32]

KT β

TGF-β saturation for apoptosis of AECs

1 × 10−10 gcm−3 [32]

KP

MCP-1 saturation for inﬂux of macrophages

5 × 10−9 gcm−3 [32]

KTα

TNF-α saturation

5 × 10−7 gcm−3 [40]

KI13

IL-13 saturation

2 × 10−7 g/cm3 [40]

KE

AEC saturation

0.1 g/cm3, estimated

ρ0

ECM saturation

10−2 gcm−3 [32]

ρ*

ECM density in health

3.26 × 10−3 gcm−3 estimated

E*

TEC density in health

0.799 gcm−3 estimated

f*

ﬁbroblast density in health

4.75 × 10−3 gcm−3 estimated

M0

source/inﬂux of macrophagesfrom blood

5 × 10−5 gcm−3 [32]

β

inﬂux rate of macrophages into interstitium

0.2 cm−1 [32]

5

doi:10.1371/journal.pone.0135097.t003

Fig 3. The dynamics of the average concentrations of cells and cytokines in units of gm/cm3 from homeostasis at day 0 to day 30. ID =
0.3 × 0.3 × 0.3 cm3.
doi:10.1371/journal.pone.0135097.g003
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Fig 4. Comparison of cells and cytokines for IPF and healthy control at day 30 from the beginning of the disease (in fraction of healthy control).
doi:10.1371/journal.pone.0135097.g004

mRNA of TGF-β reported in [42] (which can also be deduced from [43]) shows increase by at
least twice in IPF vs. control; this increase is the same for the TGF-β protein shown in Fig 4.
However, we cannot make too much out of this comparison since TGF-β has to be activated
post transcriptionally to be biologically active [20]. The mRNA expressions of TNF-α and
PDGF reported in [43] show increased levels in IPF patients, which is in qualitative agreement
with the increase in protein levels shown in Fig 4.
Figs 5 and 6 are simulations of the disease for a larger period of 300 days. We see that the
disease continue to grow but at slower rate.

Treatment studies
We can use the model to explore potential drugs. Such drugs could be, for instance, anti-TGFβ, anti-PDGF, anti-IL-13 or anti-TNF-α. Fig 7 displays the effect of treatment for mild case of
IPF, namely ID = 0.3 × 0.3 and λE0 = 2.5 × 10−3 day−1, and Fig 8 displays the effect of treatment
for severe case of IPF, namely, ID = 0.5 × 0.5 and λE0 = 3 × 10−3 day−1
Anti TNF-α. To implement the effect of anti-TNF-α (TNF-α receptor that inactivates
TNF-α and thus blocks TNF-α activity [44]), we need to modify the model replacing λMT in
Eqs (1) (2) by λMT/(1 + B1) to represent the inhibition of the activity of TNF-α. We assume
that the drug is administered starting at day 100 from the beginning of the disease. The red
curve in Figs 7 and 8 show the effect of the drug on the ECM average concentration (with B1 =
1) over a period of 300 days. The corresponding scar has a similar curve and hence it is not

PLOS ONE | DOI:10.1371/journal.pone.0135097 September 8, 2015

12 / 19

Mathematical Model of IPF

Fig 5. The dynamics of the average concentrations of cells and cytokines in units of gm/cm3 from homeostasis at day 0 to day 300. ID =
0.3 × 0.3 × 0.3 cm3.
doi:10.1371/journal.pone.0135097.g005

given here. We see that the drug has no effect on reducing the ECM. This is in agreement with
clinical phase 2 trials with Etanercept reported in [44].
The effect of the drug is introduced gradually over a period of 20 days, that is, we actually
take θ(t)B1 instead of B1, where θ(t) increases linearly from 0 to 1 over a period of 20 days. The
same procedure is used in treatment of the subsequent drugs.
Anti-PDGF. We next consider anti-PDGF treatment, by Imatinib, an inhibitor of PDGFR
and thus a blocker of PDGF activity [45]. In our model this corresponds to replacing, in Eqs
(5) and (6), λmfG by λmfG/(1 + B2). The green curve in Figs 7 and 8 show the effect of the drug
on ECM for B2 = 1. We see that the drug does not confer significant benefit, which is in agreement with phase 2 study with Imatinib.
Anti-IL-13. We next consider anti-IL-13, monoclonal antibody, a drug currently in early
phase clinical trials. Tralokinamab and lebrikizumab are two drugs delivering antibody that
blocks the action of IL-13. To implement their effect in our model we need to replace λTβ I13 in
Eq (13) by λTβ I13/(1 + B3). With the choice of B3 = 1, the blue curve in Figs 7 and 8 show no significant benefits; this seems to suggest that a moderate level of dosing will not be effective.
Anti-TGF-β. We finally consider an anti-TGFβ drug, such as Pirfenidone [46] which was
recently approved in the United States. In our model we need to replace λTβM and λTβf by λTβM/
(1 + A) and λTβf/(1 + A), and Tβ by Tβ/(1 + B) in all terms where Tβ acts to promote fibrosis. In
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Fig 6. Comparison of cells and cytokines for IPF and healthy control at day 300 from the beginning of the disease (in fraction of healthy control).
doi:10.1371/journal.pone.0135097.g006

the previous examples we showed that the drug has no benfits even at the level B = 1. For the
present anti-TGF-β drug we demonstrate a clear benefit already with small A and B. Indeed,
the cyan curve in Figs 7 and 8 show the effect of the drug on ECM for A = B = 0.1. We see that
in terms of ECM, the drug could be effective in stopping, or even slowly decreasing fibrosis.

Discussion
IPF is a disease which exhibits, as in cutaneous wounds, both pro-inflammatory features when
the alveolar epithelium is damaged and AECs begin to secrete pro-inflammatory mediators,
and anti-inflammatory features associated with unsuccessful repair processes.
In this paper we developed for the first time a mathematical model for IPF. The model
includes many of the principal players of cells and cytokines associated with the disease. The
complex geometry of the lung alveoli is simplified by using the averaging method of homogenization, which provides a way to calculate the effective interactions among the cells and cytokines. The simulations of the model agree with lung tissue data that are available from human
patients. The model can be used to explore the effect of drug treatment. Indeed, we used the
model to explore the treatment of IPF by anti-TNF-α, anti-PDGF, anti-IL-13 and anti-TGF-β.
We found that the first three drugs did not confer any benefits, while the last drug, pirfenidone,
could be effective in stopping, or even slowly decreasing fibrosis.
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Fig 7. Treatment studies for the mild case. ECM is in units of gm/cm3.
doi:10.1371/journal.pone.0135097.g007

Fig 8. Treatment studies for the severe case. ECM is in units of gm/cm3.
doi:10.1371/journal.pone.0135097.g008
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We can use the model to explore novel therapeutic approaches to the treatment of IPF. For
example, what will be the effect of combining two anti-fibrotic drugs? From Figs 5 and 7 we see
that anti-TGF-β is the most effective drug to slow the IPF progression (with A = B = 0.1) and
anti-IL-13 has only very mild benefits (with B3 = 1). However if we combine these two drugs
(at the same respective levels) we obtain significant improvement of over anti-TGF-β alone,
especially in the case of severe case of IPF, as seen in the bottom curves in Figs 5 and 7. We propose this result as an hypothesis that could be checked in clinical trials.
The present model should be viewed as a first step in the development a more comprehensive study of IPF. Such a study should include altered DNA methylation [47, 48], epigenetic
and environmental factors [49], gene mutation (e.g. of surfactant protein [50]), polymorphism
(e.g. of IL-10 [51], IL-4 [52], Muc5B [53]), and telomerase mutations [54].
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